UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2025 OR ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-37697 PERMIAN RESOURCES CORPORATION (Exact Name of Registrant as Specified in its Charter) (State of Incorporation) (I.R.S. Employer Id ...

Exhibit 99.1 Sunrun Reports Third Quarter 2025 Financial Results Aggregate Subscriber Value of $1.6 billion in Q3, 10% growth year-over-year Contracted Net Value Creation of $279 million, 35% growth year-over-year Net change in cash and restricted cash of $144 million and Cash Generation of $108 million in Q3, the sixth consecutive quarter of positive Cash Generation 1 Cash Generation guidance for 2025 of $250 million to $450 million narrowed within original range, $350 million midpoint reiterated SAN FRANC ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number 001-40599 BLEND LABS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or o ...

Exhibit 99.1 The ONE Group Reports Third Quarter 2025 Financial Results Grill portfolio optimization underway with six closures completed and up to nine additional conversions identified to enhance overall profitability Fourth-quarter sales have improved and early holiday bookings point to continued momentum Denver, CO – (BUSINESS WIRE) – November 6, 2025 – The ONE Group Hospitality, Inc. ("The ONE Group" or the "Company") (Nasdaq: STKS) today reported its financial results for the third quarter ended Septe ...

Exhibit 99.1 AerSale Reports Third Quarter 2025 Results Third Quarter 2025 Highlights MIAMI, Florida – AerSale Corporation (Nasdaq: ASLE) ("AerSale" or the "Company") today reported results for the third quarter ended September 30, 2025. The Company's revenue was $71.2 million, compared to $82.7 million in the prior year period. The decrease in year-over-year revenue was primarily the result of no sales of aircraft or engines during the current period compared to five engines sold for $22.6 million in the p ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33977 VISA INC. (Exact name of Registrant as specified in its charter) (Registrant's telephone number, including area code) S ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________ FORM 10-Q Maryland 27-5017321 (State or Other Jurisdiction of Incorporation or Organization) (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 814-00861 Fidus Investment C ...

Exhibit 99.1 Athira Pharma Reports Third Quarter 2025 Financial Results and Provides Business Update • Athira conducted the first-in-human Phase 1 (NCT 06432647) double-blind, placebo- controlled clinical trial that enrolled 80 healthy volunteers to evaluate single and multiple oral ascending doses of ATH-1105. The study was completed in November 2024 and evaluated the safety and tolerability of ATH-1105 and included measurements of pharmacokinetic outcomes. Corporate Updates Financial Results Continuing to ...

Sales Performance - Worldwide sales for Q3 2025 increased to $249.3 million, up from $244.0 million in Q3 2024, with international sales of $73.6 million compared to $72.3 million[5] - The company achieved record third quarter sales both in the U.S. and internationally, with over 20,000 pumps shipped in the U.S. and more than 9,000 pumps shipped internationally[6] - Total GAAP sales in the United States for Q3 2025 reached $175.631 million, a 2% increase from $171.650 million in Q3 2024[24] - Total sales outside the United States for Q3 2025 were $73.622 million, a 2% increase from $72.321 million in Q3 2024[24] - Total non-GAAP worldwide sales for the nine months ended September 30, 2025, were $724.353 million, reflecting a 10% increase compared to $657.555 million in the same period of 2024[26] Financial Performance - GAAP gross profit for Q3 2025 was $134.3 million, resulting in a gross margin of 54%, an improvement from 51% in Q3 2024[7] - GAAP gross profit for Q3 2025 was $134.292 million, up from $124.653 million in Q3 2024, resulting in a gross margin of 54%[26] - The operating loss for Q3 2025 was $22.9 million, or negative 9% of sales, compared to a loss of $26.1 million, or negative 11% of sales in Q3 2024[7] - The net loss for Q3 2025 was $21.2 million, an improvement from a net loss of $23.3 million in Q3 2024[7] - The company reported a GAAP net loss of $21.165 million for Q3 2025, compared to a net loss of $23.251 million in Q3 2024[26] - Non-GAAP operating loss for the nine months ended September 30, 2025, was $164.433 million, an increase from a loss of $97.900 million in the same period of 2024[26] - Non-GAAP net loss for the nine months ended September 30, 2025, was $173.003 million, compared to a loss of $96.135 million in the same period of 2024[26] Guidance and Estimates - The company reaffirmed its full-year 2025 sales guidance at approximately $1.0 billion, with U.S. sales expected to be around $700 million and international sales approximately $300 million[10] - Gross margin for the full year 2025 is estimated to be between 53% and 54% of sales[10] - Adjusted EBITDA margin for the full year is estimated to be approximately negative 5% of sales, revised from approximately 3%[10] - Non-cash charges included in cost of goods sold and operating expenses are estimated to be approximately $115 million for the full year 2025[10] Other Developments - The company received FDA clearance for the extended wear use of the SteadiSet Infusion Set and filed for Android mobile control of the Tandem Mobi insulin delivery system[6] - The company recorded $11.2 million in impairment charges related to restructuring costs in Q1 2025[27] - The Tandem Choice program concluded in 2024, with no impact on sales for this program in 2025[24] - Free cash flow for Q3 2025 was $4.172 million, down from $21.542 million in Q3 2024[26]

Financial Performance - Artivion reported third quarter 2025 revenue of $113.4 million, an increase of 18% on a GAAP basis and 16% on a non-GAAP constant currency basis compared to Q3 2024[6] - Net income for Q3 2025 was $6.5 million, or $0.13 per fully diluted share, compared to a net loss of $(2.3) million, or $(0.05) per fully diluted share in Q3 2024[8] - Adjusted EBITDA increased by 39% to $24.6 million in Q3 2025, up from $17.7 million in Q3 2024[6] - Total revenues for the three months ended September 30, 2025, increased to $113,388,000, up 18.4% from $95,779,000 in the same period of 2024[26] - Gross margin for the three months ended September 30, 2025, was $74,395,000, representing a 65.6% margin compared to $61,009,000 in 2024[26] - Operating income for the three months ended September 30, 2025, rose to $12,536,000, compared to $4,387,000 in 2024, marking a 185.5% increase[26] - Total product revenues for the nine months ended September 30, 2025, were $253.907 million, reflecting a 17% increase from $215.568 million in the same period of 2024[30] - Free cash flows for Q3 2025 amounted to $17.653 million, significantly higher than $7.816 million in Q3 2024[30] Revenue Breakdown - Stent grafts revenue grew by 38%, On-X by 25%, preservation services by 5%, and BioGlue by 2% year-over-year in Q3 2025[4] - Aortic stent grafts generated $39.585 million in Q3 2025, up 31% from $28.643 million in Q3 2024[28] - On-X product revenues increased by 23% to $26.797 million in Q3 2025, compared to $21.478 million in Q3 2024[28] - Preservation services revenues decreased by 5% to $71.431 million for the nine months ended September 30, 2025, compared to $75.661 million in the same period of 2024[30] Guidance and Projections - Artivion raised its full year 2025 revenue guidance to a range of $439 to $445 million, reflecting constant currency growth of 13% to 14%[9] - The company also raised its adjusted EBITDA guidance for 2025, now expecting growth of 24% to 28%, with adjusted EBITDA projected to be between $88 to $91 million[10] - Artivion aims to grow adjusted EBITDA at twice the rate of constant currency revenue growth, indicating strong operational momentum[7] Clinical and Operational Developments - Artivion enrolled the first patient in the ARTIZEN trial for Arcevo, marking a significant milestone in its clinical programs[6] - Positive clinical data from AMDS PERSEVERE and PROTECT trials were presented, validating the benefits of AMDS technology[5] Balance Sheet and Cash Flow - Cash and cash equivalents increased to $73,426,000 as of September 30, 2025, up from $53,463,000 at the end of 2024[22] - Total current assets reached $337,498,000 as of September 30, 2025, compared to $290,080,000 at the end of 2024, reflecting a 16.3% increase[22] - Total liabilities decreased to $418,968,000 as of September 30, 2025, down from $512,901,000 at the end of 2024[22] - Total assets increased to $857,662,000 as of September 30, 2025, from $789,101,000 at the end of 2024, representing an 8.7% growth[22] Expenses - Research and development expenses for the three months ended September 30, 2025, were $8,078,000, up from $6,605,000 in 2024, indicating a 22.3% increase[26] - General, administrative, and marketing expenses increased to $57.281 million in Q3 2025 from $50.017 million in Q3 2024[30] - The company reported a comprehensive income of $7,043,000 for the three months ended September 30, 2025, compared to $4,045,000 in 2024[26]